Rashmi K. Murthy, MD, discusses selecting therapy for patients with HER2-positive breast cancer in the curative setting in a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer.
Original Article: The State of HER2+ Breast Cancer in the Curative Setting